Search
Toloxatone
go.drugbank.com/drugs/DB09245ExperimentalToloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388].
NGD-4715
go.drugbank.com/drugs/DB06027ExperimentalNGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.
ILY101
go.drugbank.com/drugs/DB05059InvestigationalILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on d...
Progabide
go.drugbank.com/drugs/DB00837ExperimentalProgabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors.
Ethyl macadamiate
go.drugbank.com/drugs/DB11243ApprovedEthyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products and skin care products as an emollient and skin conditioning agent.
Viper antivenom
go.drugbank.com/drugs/DB14114ApprovedInvestigationalANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation
Probenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalProbenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
Synonyms: 4-(Di-n-propylsulfamoyl)benzoesäure, p-(Dipropylsulfamoyl)benzoic acidCategories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP3A InducersTiagabine
go.drugbank.com/drugs/DB00906ApprovedTiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesiCo-007
go.drugbank.com/drugs/DB05268Investigationalcompound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR
Gadobutrol
go.drugbank.com/drugs/DB06703ApprovedInvestigationalDue to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume. … [A7001] Like other GBCA, gadobutrol usage carries the risk of nephrogenic systemic fibrosis (NSF) due to the dissociation of gadolinium from the chelates, although gadobutrol tends to have a lower risk